Generic Attruby Availability

Last updated on Apr 10, 2025.

Attruby is a brand name of acoramidis, approved by the FDA in the following formulation(s):

ATTRUBY (acoramidis hydrochloride - tablet;oral)

• Manufacturer: BRIDGEBIO PHARMA
  Approval date: November 22, 2024
  Strength(s): EQ 356MG BASE ^[RLD]

Is there a generic version of Attruby available?

No. There is currently no therapeutically equivalent version of Attruby available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Attruby. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
  Patent 10,398,681
  Issued: September 3, 2019
  Inventor(s): Graef; Isabella A. et al.
  Assignee(s): The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
  

  Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

  Patent expiration dates:

  • May 5, 2031
    
    ✓ 
    Drug product
• Process for preparing AG-10, its intermediates, and salts thereof
  Patent 10,513,497
  Issued: December 24, 2019
  Inventor(s): Chand; Pooran et al.
  Assignee(s): EIDOS THERAPEUTICS, INC. (San Francisco, CA)
  

  Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib ##STR00001##
  as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.

  Patent expiration dates:

  • February 16, 2038
    
    ✓ 
    Drug substance
• Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
  Patent 10,842,777
  Issued: November 24, 2020
  Inventor(s): Graef; Isabella A. et al.
  Assignee(s): The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
  

  Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

  Patent expiration dates:

  • May 5, 2031
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
• Methods of treating TTR amyloidosis using AG10
  Patent 11,058,668
  Issued: July 13, 2021
  Inventor(s): Sinha; Uma et al.
  Assignee(s): EIDOS THERAPEUTICS, INC. (San Francisco, CA)
  

  Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.

  Patent expiration dates:

  • March 22, 2039
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
• Formulations of AG10
  Patent 11,260,047
  Issued: March 1, 2022
  Inventor(s): Jernelius; Jesper et al.
  Assignee(s): EIDOS THERAPEUTICS, INC. (San Francisco, CA)
  

  The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.

  Patent expiration dates:

  • August 16, 2039
    
    ✓ 
    Drug product
• Processes for preparing AG-10, its intermediates, and salts thereof
  Patent 11,919,865
  Issued: March 5, 2024
  Inventor(s): Chand; Pooran et al.
  Assignee(s): EIDOS THERAPEUTICS, INC. (San Francisco, CA)
  

  Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib ##STR00001##
  as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.

  Patent expiration dates:

  • February 16, 2038
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
• Formulations of AG10
  Patent 12,005,043
  Issued: June 11, 2024
  Inventor(s): Jernelius; Jesper et al.
  Assignee(s): EIDOS THERAPEUTICS, INC. (Palo Alto, CA)
  

  The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.

  Patent expiration dates:

  • August 16, 2039
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
    ✓ 
    Drug product
• Methods of treating TTR amyloidosis using AG10
  Patent 12,070,449
  Issued: August 27, 2024
  Inventor(s): Sinha; Uma et al.
  Assignee(s): EIDOS THERAPEUTICS, INC. (Palo Alto, CA)
  

  Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects

  Patent expiration dates:

  • March 22, 2039
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
• Identification of stabilizers of multimeric proteins
  Patent 8,877,795
  Issued: November 4, 2014
  Inventor(s): Graef; Isabella A. et al.
  Assignee(s): The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
  

  Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

  Patent expiration dates:

  • May 5, 2031
    
    ✓ 
    Drug product
• Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
  Patent 9,169,214
  Issued: October 27, 2015
  Inventor(s): Graef; Isabella A. et al.
  Assignee(s): The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
  

  Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

  Patent expiration dates:

  • May 5, 2031
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
    ✓ 
    Drug product
• Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
  Patent 9,642,838
  Issued: May 9, 2017
  Inventor(s): Graef; Isabella A. et al.
  Assignee(s): The Board of Trustees of the Leland Standford Junior University (Palo Alto, CA)
  

  Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

  Patent expiration dates:

  • May 5, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
  Patent 9,913,826
  Issued: March 13, 2018
  Inventor(s): Graef; Isabella A. et al.
  Assignee(s): The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
  

  Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

  Patent expiration dates:

  • May 5, 2031
    
    ✓ 
    Patent use: TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • November 22, 2029 - NEW CHEMICAL ENTITY
  • November 22, 2031 - TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS(ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR DEATH AND CARDIOVASCULAR-RELATED HOSPITALIZATION

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer